Key result
Selexipag, an oral prostacyclin receptor agonist, improves hemodynamics and reduces clinical worsening in patients with pulmonary arterial hypertension.
This review summarizes the development and clinical use of selexipag, an oral prostacyclin receptor agonist, for the treatment of pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Supports selexipag consideration in PAH; leaves open need for comparative trials versus other agents.
Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag.
No takes yet. Share an insight, caveat, or question.
Hardin et al. (2016) conducted a review in Pulmonary arterial hypertension. Selexipag was evaluated. Selexipag, an oral prostacyclin receptor agonist, improves hemodynamics and reduces clinical worsening in patients with pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: